(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2025 (18.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/193691 A1

(51) International Patent Classification:
A61K 31/395 (2006.01) *A61K 31/13* (2006.01)
A61K 31/505 (2006.01) *A61K 31/33* (2006.01)
A61K 31/517 (2006.01) *A61K 31/4427* (2006.01)

(21) International Application Number:
PCT/US2025/019362

(22) International Filing Date:
11 March 2025 (11.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/564,383 12 March 2024 (12.03.2024) US

(71) Applicant: **CASMA THERAPEUTICS, INC.** [US/US]; 400 Technology Square, Suite 201, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **FORTANET, Jorge Garcia**; c/o Casma Therapeutics, Inc., 400 Technology Square, Suite 201, Cambridge, Massachusetts 02139 (US). **KELLY, John**; c/o Casma Therapeutics, Inc., 400 Technology Square, Suite 201, Cambridge, Massachusetts 02139 (US). **BAIRD, Daniel W.**; c/o Casma Therapeutics, Inc., 400 Technology Square, Suite 201, Cambridge, Massachusetts 02139 (US).

(74) Agent: **SHINALL, Michael A.** et al.; CHOATE, HALL & STEWART LLP, Two International Place, Boston, Massachusetts 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: BICYCLIC HETEROAROMATIC COMPOUNDS AS TRPML MODULATORS

(57) Abstract: The present disclosure provides compounds that are useful as modulators of TRPML, e.g., TPRML1, TRPML2, and/or TRPML3. In some embodiments, a compound described herein is a compound represented by Formula I: or a pharmaceutically acceptable salt thereof. In some embodiments, a compound described herein is useful in the treatment of diseases, disorders, and conditions described herein, such as those associated with TRPML modulation.



I

WO 2025/193691 A1